OPC Pharmaceutical Joint Stock Company
HHOSE:OPC19,400.00
VND
0.00
(0.00%)
ISIN
VN000000OPC9
Return %
Stock
S&P 500
1Y
2.01
14.20
3Y
-0.88
81.12
5Y
-5.03
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Xuan Huong Thi Pham
- Full Time Employees
- 867
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Ho Chi Minh City Vietnam
- IPO Date
- Oct 20, 2008
- Website
- opcpharma.com
- Similar Companies
- Business
- OPC Pharmaceutical Joint Stock Company is a Vietnam-based pharmaceutical enterprise primarily engaged in the research, cultivation, development, manufacture, and commercialization of traditional herbal medicines, phytopharmaceuticals, dietary supplements, and healthcare products. Founded in 1977 and headquartered in Ho Chi Minh City, Vietnam, the company operates across domestic over-the-counter and ethical hospital channels as well as international export markets, managing an integrated business model spanning medicinal herb cultivation, pharmaceutical extraction, formulation, and wholesale distribution. The company's product and service offerings comprise specialized therapeutic categories and contract capabilities, including urological and nephrological remedies, led by its flagship Kim Tien Thao formulation under the Ong Gia brand for kidney and urinary calculi treatment; pediatric and adult respiratory therapies, including HoAstex and HoAstex-S herbal cough syrups; medicated external applications, featuring Dau Khuynh Diep eucalyptus oil under the Me Bong Con brand; central nervous system and sedative treatments, including Mimosa and Dinh Tam; musculoskeletal and anti-inflammatory medications, such as Fengshi-OPC; cardiovascular and metabolic management drugs, including Cardiopan and Cholestin; traditional restorative tonics, including Hoan Luc Vi and Hoan Bat Vi; vitamins, minerals, and effervescent nutritional supplements; and raw herbal material processing, botanical extraction, softgel encapsulation, contract manufacturing, and the distribution of medical supplies and personal care products. The company operates manufacturing facilities and herb processing centers certified under GMP-WHO, GLP, GSP, and GACP-WHO standards, supported by key subsidiaries including OPC Binh Duong Pharmaceutical Co., Ltd., OPC Bac Giang Pharmaceutical Joint Stock Company, and Central Pharmaceutical Joint Stock Company No. 25 (Uphace). In recent developments, OPC Pharmaceutical Joint Stock Company has executed several strategic alliances and operational upgrades to advance its research infrastructure and transition toward higher-value pharmaceutical segments. The company entered into a formal collaboration with the Faculty of Pharmacy at the University of Medicine and Pharmacy at Ho Chi Minh City to conduct joint clinical research, pharmaceutical formulation studies, and workforce development. To strengthen raw material standardization, the company established a cooperation agreement with China Medical University aimed at enhancing the value chain and traceability of Vietnamese medicinal plants. Furthermore, the company has pursued digital transformation initiatives, collaborating with partners such as Aribio to digitalize natural medicine databases and support advanced R&D. Operationally, the company is advancing a strategic shift toward modern, high-value phytomedicines and aligning manufacturing standards toward EU-GMP certification to expand its institutional hospital market tender presence and broaden export capabilities.